GENERAL ICD- C61: Prostate cancer Page 2 of 18 ICD- C61: Malignant neoplasm of prostate Period of diagnosis % Relative survival N=46,

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "GENERAL ICD- C61: Prostate cancer Page 2 of 18 ICD- C61: Malignant neoplasm of prostate Period of diagnosis % Relative survival N=46,"

Transcription

1 Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD- C61: Prostate cancer Survival Year of diagnosis Patients 7,45 49,513 Diseases 7,45 49,514 Cases evaluated 6,621 4,8 Creation date 8/22/217 Export date 8/16/217 Population (males) 2.38 m BERLIN GERMANY BAVARIA MUNICH Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, Germany E-ICD--C61-Prostate-cancersurvival.pdf

2 GENERAL ICD- C61: Prostate cancer Page 2 of 18 ICD- C61: Malignant neoplasm of prostate Period of diagnosis % Relative survival N=46, Figure 1a. Relative survival of patients with prostate cancer by period of diagnosis. Included in the evaluation are 46,592 cases diagnosed between 1988 and 215. The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers. Period of diagnosis n=6,613 n=18,633 n=21,346 obs. % rel. % obs. % rel. % obs. % rel. % Table 1b. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by period of diagnosis for period (N=46,592). Period of diagnosis n=6, % n=18,633 4.% 27+ n=21, %

3 GENERAL ICD- C61: Prostate cancer Page 3 of 18 ICD- C61: Malignant neoplasm of prostate Year of diagnosis % Relative survival N=39,979 1 Year of diagnosis 1998 n=1, % n=1, % 2 n=1, % 21 n=1, % 22 n=2, % 23 n=2, % 24 n=2,68 6.7% 25 n=2,62 6.6% 26 n=2,52 6.3% 27 n=2, % 28 n=2,68 6.7% n=2, % 2 n=2, % 211 n=2, % 212 n=2, % 213 n=2, % 214 n=2, % 215 n=1,196 3.% SEER n=585,397 Figure 1c. Relative survival of patients with prostate cancer by year of diagnosis. Included in the evaluation are 39,979 cases diagnosed between 1998 and 215. The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2 to 214, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER. Year of diagnosis n=1,255 n=1,266 n=1,395 n=1,483 n=2,688 n=2,726 n=2,68 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. %

4 GENERAL ICD- C61: Prostate cancer Page 4 of 18 Year of diagnosis cont'd n=2,62 n=2,52 n=2,964 n=2,68 n=2,448 n=2,372 n=2,558 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % Year of diagnosis cont'd n=2,638 n=2,295 n=2,195 n=1,196 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % Table 1d. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by year of diagnosis for period (N=39,979).

5 GENERAL ICD- C61: Prostate cancer Page 5 of 18 ICD- C61: Malignant neoplasm of prostate Total cohort % Survival N=39,979 N= Observed Expected Relative Figure 2a. Observed, expected and relative survival of the total cohort with prostate cancer. Included in the evaluation are 39,979 cases diagnosed between 1998 and 215. Group Total cohort n=39,979 obs. % rel. % Table 2b. Observed (obs.) and relative (rel.) survival of the total cohort with prostate cancer for period (N=39,979). Group Total cohort n=39,979.%

6 GENERAL ICD- C61: Prostate cancer Page 6 of 18 ICD- C61: Malignant neoplasm of prostate Age category % Observed survival N=46, Figure 3a. Observed survival of patients with prostate cancer by age category. Included in the evaluation are 46,592 cases diagnosed between 1988 and 215. Age category -59 yrs n=6,4 13.8% 6-69 yrs n=18, % 7-79 yrs n=16, % 8+ yrs n=4,829.4% ICD- C61: Malignant neoplasm of prostate Age category % Relative survival N=46, Age category -59 yrs n=6,4 13.8% 6-69 yrs n=18, % 7-79 yrs n=16, % 7 8+ yrs n=4,829.4% Figure 3b. Relative survival of patients with prostate cancer by age category. Included in the evaluation are 46,592 cases diagnosed between 1988 and 215.

7 GENERAL ICD- C61: Prostate cancer Page 7 of 18 Age category -59 yrs 6-69 yrs 7-79 yrs 8+ yrs n=6,4 n=18,449 n=16,94 n=4,829 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % Table 3c. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by age category for period (N=46,592).

8 GENERAL ICD- C61: Prostate cancer Page 8 of 18 ICD- C61: Malignant neoplasm of prostate TNM staging % Relative survival N=38,357 1 TNM staging T1 n=6, % T2 n=18, % T3 n=9, % T4 n=1,73 4.4% N n=23, % N+ n=2, % NX n=6, % M1 n=2,92 7.6% NA/NOS n=8, % Figure 4a. Relative survival of patients with prostate cancer by TNM staging. For 38,482 of 46,592 cases diagnosed between 1988 and 215 valid data could be obtained for this item. For a total of 38,357 cases an evaluable classification was established. The accumulated percentage exceeds the % value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 8,235 patients with missing values regarding TNM staging (17.7 % of 46,592 patients, the percent values of all other categories are related to n=38,357). TNM staging T1 T2 T3 T4 N N+ NX n=6,438 n=18,612 n=9,988 n=1,73 n=23,786 n=2,978 n=6,765 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. %

9 GENERAL ICD- C61: Prostate cancer Page 9 of 18 TNM staging cont'd M1 NA/NOS n=2,92 n=8,235 obs. % rel. % obs. % rel. % Table 4b. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by TNM staging for period (N=38,357).

10 GENERAL ICD- C61: Prostate cancer Page of 18 ICD- C61: Malignant neoplasm of prostate TNM staging % Relative survival N=32,594 1 TNM staging T1 n=5, % T2 n=16, % T3 n=7, % T4 n=1, % N n=2, % N+ n=2,38 7.3% NX n=5, % M1 n=2,47 7.4% NA/NOS n=7, % Figure 4c. Relative survival of patients with prostate cancer by TNM staging. For 32,77 of 39,979 cases diagnosed between 1998 and 215 valid data could be obtained for this item. For a total of 32,594 cases an evaluable classification was established. The accumulated percentage exceeds the % value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 7,385 patients with missing values regarding TNM staging (18.5 % of 39,979 patients, the percent values of all other categories are related to n=32,594). TNM staging T1 T2 T3 T4 N N+ NX n=5,46 n=16,743 n=7,915 n=1,116 n=2,486 n=2,38 n=5,18 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. %

11 GENERAL ICD- C61: Prostate cancer Page 11 of 18 TNM staging cont'd M1 NA/NOS n=2,47 n=7,385 obs. % rel. % obs. % rel. % Table 4d. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by TNM staging for period (N=32,594).

12 GENERAL ICD- C61: Prostate cancer Page 12 of 18 ICD- C61: Malignant neoplasm of prostate Extent of disease % Conditional relative 5 year survival N=38, Extent of disease Local n=33, % Regional n=2, % Distant n=2,92 7.6% 7 NA/NOS n=8, % Time since diagnosis (years) Figure 4e. Conditional relative 5-year survival of patients with prostate cancer by extent of disease. For 38,482 of 46,592 cases diagnosed between 1988 and 215 valid data could be obtained for this item. For a total of 38,313 cases an evaluable classification was established. The grey line represents the subgroup of 8,279 patients with missing values regarding extent of disease (17.8 % of 46,592 patients, the percent values of all other categories are related to n=38,313). Extent of disease Local Regional Distant NA/NOS Cond. Cond. Cond. Cond. surv. % surv. % surv. % surv. % n 5 yrs n 5 yrs n 5 yrs n 5 yrs 33, , , , , , , , , , , , , , , , , , , , , ,8.8 1, , , , , , , , , , Table 4f. Conditional relative 5-year survival of patients with prostate cancer by extent of disease for period (N=38,313). Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (= %) under the condition of being alive for a certain time period (x-axis in Figure 4c). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease= Local, who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 1.6% (n=26,754).

13 PROGRESSION ICD- C61: Prostate cancer Page 13 of 18 % Time to first progression (TTP) N=37, Type of progression Any type (CI) Events=6,646 Any type (1-KM) Events=6,646 Local relapse (CI) Events=1,531 Local relapse (1-KM) Events=1,531 Lymph node (CI) Events=499 Lymph node (1-KM) Events=499 Distant metastasis (CI) Events=3,112 Distant metast. (1-KM) Events=3,112 NOS (CI) Events=2,431 NOS (1-KM) Events=2, Figure 5a. Time to first progression of 37,228 patients with prostate cancer diagnosed between 1998 and 215 (in solid cancers M only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting. Type of progression Distant Any type (CI) Any type (1-KM) Local relapse (CI) Local relapse (1-KM) Lymph node (CI) Lymph node (1-KM) metastasis (CI) n=37,228 n=37,228 n=37,228 n=37,228 n=37,228 n=37,228 n=37,228 % % % % % % %

14 PROGRESSION ICD- C61: Prostate cancer Page 14 of 18 Type of progression Distant cont'd metast. (1- NOS (CI) NOS (1-KM) KM) n=37,228 n=37,228 n=37,228 % % % Table 5b. Time to first progression of patients with prostate cancer for period (N=37,228).

15 PROGRESSION ICD- C61: Prostate cancer Page 15 of 18 ICD- C61: Malignant neoplasm of prostate Progression type % Observed post-progression survival N=7, Figure 5c. Observed post-progression survival of 7,513 patients with prostate cancer diagnosed between 1998 and 215. These 7,513 patients with documented progression events during their course of disease represent 19. % of the totally 39,615 evaluated cases (incl. M1, n=2,387, 6. %). Patients with cancer relapse documented via death certificates only were excluded (n=1,52, 3.8 %). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease. Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement not specified is the only information in registries regarding relapse of the disease. The category Any type denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the % value because patients are potientially considered in more than one subgroup. Type of progression Any type Local relapse Lymph node Distant metastasis NOS n=7,513 n=1,654 n=558 n=4,213 n=2,433 % % % % % Table 5d. Observed post-progression survival of patients with prostate cancer for period (N=7,513). Type of progression Any type n=7,513.% Local relapse n=1, % Lymph node n= % Distant metastasis n=4, % NOS n=2, %

16 PROGRESSION ICD- C61: Prostate cancer Page 16 of 18 ICD- C61: Malignant neoplasm of prostate Type of Progression: Distant metastasis % Observed post-progression survival by period of progression date N=5, Figure 5e. Observed post-progression (distant metastasis) survival of 5,346 patients with prostate cancer diagnosed between 1988 and 215 by period of progression. Period of progression n=741 n=1,6 n=2,975 % % % Table 5f. Observed post-progression (distant metastasis) survival of patients with prostate cancer for period by period of progression (N=5,346). Period of progression n= % n=1,6.5% 27+ n=2, %

17 USAGE ICD- C61: Prostate cancer Page 17 of 18 Shortcuts MCR Munich Cancer Registry, Germany NCI National Cancer Institute, USA SEER Surveillance, Epidemiology, and End Results, USA UICC Union for International Cancer Control, Geneva DCO Death certificate only NA Not available NOS Not otherwise specified Death certificate provides the only notification to the registry. OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause RS Relative survival Survival compared to general population, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival AS Assembled survival Assembled chart of observed, expected, relative survival CS Conditional survival Survival probability under the condition of surviving a given period of time TTP Time to progression Time to first progression / relapse Date of entry: diagnosis Event: (progression/ relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression 1-KM CI 1 minus Kaplan-Meier estimator ( inverse Kaplan-Meier estimator) Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice) PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause Recommended Citation Munich Cancer Registry. Survival ICD- C61: Prostate cancer [Internet]. 217 [updated 217 Aug 22; cited 217 Oct 1]. Available from: E-ICD--C61- Prostate-cancer-survival.pdf Copyright The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced. Disclaimer The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

18 INDEX ICD- C61: Prostate cancer Page 18 of 18 Fig./Tbl. Index of figures and tables Page 1a Relative survival by period of diagnosis (chart) 2 1b Survival by period of diagnosis (table) 2 1c Relative survival by year of diagnosis (chart) 3 1d Survival by year of diagnosis (table) 3 2a Survival of total cohort (chart) 5 2b Survival of total cohort (table) 5 3a Observed survival by age category (chart) 6 3b Relative survival by age category (chart) 6 3c Survival by age category (table) 7 4a Relative survival by TNM staging (chart) 8 4b Survival by TNM staging (table) 8 4c Relative survival by TNM staging (chart) 4d Survival by TNM staging (table) 4e Conditional survival by extent of disease (chart) 12 4f Conditional survival by extent of disease (table) 12 5a Time to first progression (chart) 13 5b Time to first progression (table) 13 5c Observed post-progression survival (chart) 15 5d Observed post-progression survival (table) 15 5e Observed post-progression survival by period of progression (chart) 16 5f Observed post-progression survival by period of progression (table) 16

GENERAL ICD- C73: Thyroid cancer Page 2 of 15 ICD- C73: Malignant neoplasm of thyroid gland Period of diagnosis % Relative survival N=7,95 9

GENERAL ICD- C73: Thyroid cancer Page 2 of 15 ICD- C73: Malignant neoplasm of thyroid gland Period of diagnosis % Relative survival N=7,95 9 Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD- C73: Thyroid cancer Survival Year of diagnosis 1988-1997 1998-215 Patients 953 7,13 Diseases 957 7,18 Cases evaluated

More information

Cases by year of diagnosis, proportions of further malignancies, deaths, and active follow-up (ALL PATIENTS)

Cases by year of diagnosis, proportions of further malignancies, deaths, and active follow-up (ALL PATIENTS) Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 D32: Meninges neoplasm Incidence and Mortality Year of diagnosis 1998-2015 Patients 2,545 Diseases 2,547 Creation date 02/01/2018

More information

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume

More information

An Overview of Survival Statistics in SEER*Stat

An Overview of Survival Statistics in SEER*Stat An Overview of Survival Statistics in SEER*Stat National Cancer Institute SEER Program SEER s mission is to provide information on cancer statistics in an effort to reduce the burden of cancer among the

More information

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage

More information

The projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung*

The projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung* Conditional Survival Among Patients With Carcinoma of the Lung* Ray M. Merrill, PhD, MPH; Donald Earl Henson, MD; and Michael Barnes, PhD Objective: One- and 5-year probabilities of survival or death change

More information

Chapter 13 Cancer of the Female Breast

Chapter 13 Cancer of the Female Breast Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results

More information

Report on Cancer Statistics in Alberta. Melanoma of the Skin

Report on Cancer Statistics in Alberta. Melanoma of the Skin Report on Cancer Statistics in Alberta Melanoma of the Skin November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of

More information

EXPLORING THE INTERNAL CONSISTENCY OF REGISTRY DATA ON STAGE OF DISEASE AT DIAGNOSIS

EXPLORING THE INTERNAL CONSISTENCY OF REGISTRY DATA ON STAGE OF DISEASE AT DIAGNOSIS EXPLORING THE INTERNAL CONSISTENCY OF REGISTRY DATA ON STAGE OF DISEASE AT DIAGNOSIS Richard Porter Catherine N. Correa John P. Fulton Holly L. Howe Chris Newton Judy Nowak Steven D. Roffers This paper

More information

Directly Coded Summary Stage Prostate Cancer

Directly Coded Summary Stage Prostate Cancer Directly Coded Summary Stage Prostate Cancer National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control, Cancer Surveillance Branch Directly Coded Summary

More information

Trends in Lung Cancer Morbidity and Mortality

Trends in Lung Cancer Morbidity and Mortality Trends in Lung Cancer Morbidity and Mortality American Lung Association Epidemiology and Statistics Unit Research and Program Services Division November 2014 Table of Contents Trends in Lung Cancer Morbidity

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.

More information

CERVIX MEASURE SPECIFICATIONS

CERVIX MEASURE SPECIFICATIONS Cancer Programs Practice Profile Reports (CP 3 R) CERVIX MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve

More information

THE ISSUE OF STAGE AT DIAGNOSIS

THE ISSUE OF STAGE AT DIAGNOSIS THE ISSUE OF STAGE AT DIAGNOSIS IN SURVIVAL ANALYSIS Pamela Minicozzi Analytical Epidemiology and Health Impact Unit Department of Preventive and Predictive Medicine, Fodazione IRCCS Istituto Nazionale

More information

Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis

Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis www.nature.com/scientificreports Received: 1 May 2017 Accepted: 30 August 2017 Published: xx xx xxxx OPEN Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma:

More information

Global surveillance of cancer survival

Global surveillance of cancer survival Global surveillance of cancer survival Claudia Allemani Helena Carreira Rhea Harewood Devon Spika Xiao-Si Wang Finian Bannon Jane Ahn Loraine Marrett Donna Turner Thomas C Tucker Hannah K Weir CONCORD

More information

Testicular Malignancies /8/15

Testicular Malignancies /8/15 Collecting Cancer Data: Testis 2014-2015 NAACCR Webinar Series January 8, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

Methods and Limitations Overview

Methods and Limitations Overview Methods and Limitations Overview Geographic Description of Cuyahoga County Cuyahoga County is comprised of 36 neighborhoods within the City of Cleveland and 58 suburban municipalities. To better understand

More information

Cancer of lymph nodes survival rate

Cancer of lymph nodes survival rate Cancer of lymph nodes survival rate Search 14-3-2016 Survival rates of pancreatic cancer are based on outcomes of people who've had the disease. Find the survival rates for pancreatic cancer here. 18-12-2017

More information

1 Purposes and Principles of Cancer Staging

1 Purposes and Principles of Cancer Staging Purposes and Principles of Cancer Staging INTRODUCTION AND OVERVIEW The extent or stage of cancer at the time of diagnosis is a key factor that defines prognosis and is a critical element in determining

More information

Physician On-line Staging Application. Darlene Dale Head, PMH Cancer Registry

Physician On-line Staging Application. Darlene Dale Head, PMH Cancer Registry Physician On-line Staging Application Darlene Dale Head, PMH Cancer Registry NAACCR 2004 Outline Overview of Princess Margaret Hospital History of Staging at PMH Steps to On-Line Physician Staging at PMH

More information

Linking Oncotype Dx results to SEER data and patient report to assess challenges in individualizing breast cancer care

Linking Oncotype Dx results to SEER data and patient report to assess challenges in individualizing breast cancer care Linking Oncotype Dx results to SEER data and patient report to assess challenges in individualizing breast cancer care June 16, 2015 NAACCR, Charlotte, NC Ann Hamilton, Ph.D. Keck School of Medicine, University

More information

Perigastric lymph node metastases in gastric cancer: comparison of different staging systems

Perigastric lymph node metastases in gastric cancer: comparison of different staging systems Gastric Cancer (1999) 2: 201 205 Original article 1999 by International and Japanese Gastric Cancer Associations Perigastric lymph node metastases in gastric cancer: comparison of different staging systems

More information

Statin use and reduced cancer-related mortality Journal Club 24/11/12

Statin use and reduced cancer-related mortality Journal Club 24/11/12 Statin use and reduced cancer-related mortality Journal Club 24/11/12 Presenter: Anas Sarhan Moderator: Prof. Ronan Conroy The new england journal of medicine original article Statin Use and Reduced Cancer-Related

More information

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.

More information

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System Kyle L. Ziegler, CTR California Cancer Registry U.C. Davis Health System Overview New Data Items Reportability Clarifications New Coding Rules Grade ICD-O-3 Changes Collaborative Stage v0205 2 New Data

More information

Adjuvant Radiotherapy for completely resected NSCLC

Adjuvant Radiotherapy for completely resected NSCLC Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local

More information

Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients

Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients INGO ALLDINGER 1,2, QIN YANG 3, CHRISTIAN PILARSKY 1, HANS-DETLEV SAEGER 1, WOLFRAM T. KNOEFEL

More information

ORIGINAL ARTICLE. A Population-Based Analysis of Survival and Prognostic Factors

ORIGINAL ARTICLE. A Population-Based Analysis of Survival and Prognostic Factors Esthesioneuroblastoma ORIGINAL ARTICLE A Population-Based Analysis of Survival and Prognostic Factors Daniel Jethanamest, MD; Luc G. Morris, MD; Andrew G. Sikora, MD, PhD; David I. Kutler, MD Objectives:

More information

Primary Localization and Tumor Thickness as Prognostic Factors of Survival in Patients with Mucosal Melanoma

Primary Localization and Tumor Thickness as Prognostic Factors of Survival in Patients with Mucosal Melanoma Primary Localization and Tumor Thickness as Prognostic Factors of Survival in Patients with Mucosal Melanoma Tarun Mehra 1,4 *, Gerd Grözinger 2, Steven Mann 2, Emmanuella Guenova 3, Rudolf Moos 4, Martin

More information

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage

More information

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in

More information

Racial and Social Economic Factors Impact on the Cause Specific Survival of Pancreatic Cancer: A SEER Survey

Racial and Social Economic Factors Impact on the Cause Specific Survival of Pancreatic Cancer: A SEER Survey DOI:http://dx.doi.org/10.7314/APJCP.2013.14.1.159 RESEARCH ARTICLE Racial and Social Economic Factors Impact on the Cause Specific Survival of Pancreatic Cancer: A SEER Survey Rex Cheung Abstract Background:

More information

Stage 3 ovarian cancer survival rate

Stage 3 ovarian cancer survival rate Stage 3 ovarian cancer survival rate Gogamz Menu The latest ovarian cancer survival statistics for the UK for Health Professionals. See data for age, trends over time, stage at diagnosis and more. 5-8-2014

More information

Carcinoembryonic Antigen

Carcinoembryonic Antigen Other Names/Abbreviations CEA 190.26 - Carcinoembryonic Antigen Carcinoembryonic antigen (CEA) is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring

More information

Carcinoembryonic Antigen

Carcinoembryonic Antigen Other Names/Abbreviations CEA 190.26 - Carcinoembryonic Antigen Carcinoembryonic antigen (CEA) is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring

More information

Ian Landry, MPH Beth Schmidt, MSPH

Ian Landry, MPH Beth Schmidt, MSPH Mary Charlton, PhD Bobbi Matt, CTR Mary Anne Lynch, MPH Vivien Chen, PhD Ian Landry, MPH Beth Schmidt, MSPH Response to EGFR inhibitors is poorer among Stage IV colorectal cancer (CRC) patients with KRAS

More information

Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study

Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty

More information

Life Science Journal 2014;11(7)

Life Science Journal 2014;11(7) Life Science Journal 4;(7) http://www.lifesciencesite.com Impact of primary tumor resection on response and survival in metastatic breast cancer patients Enas. A. Elkhouly¹, Eman. A. Tawfik ¹, Alaa. A.

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery

Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation

More information

Cancer prevalence. Chapter 7

Cancer prevalence. Chapter 7 Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.

More information

ICD-O CODING Third Edition

ICD-O CODING Third Edition Slide 1 ICD-O CODING Third Edition PART I An introduction to the ICD-O-3 Coding Manual This is part 1 of a 2-part slide presentation. Use the navigation buttons below this panel to advance the slides.

More information

Cancer in zimbabwe 2014 report

Cancer in zimbabwe 2014 report Cancer in zimbabwe 2014 report Categories : Health talks with Dr Chireka Date : 13th October 2016 Cancer in Zimbabwe By Dr Brighton Chireka On Tuesday, the 11th October 2016, I was privileged to receive

More information

Current Status and Future Medical Perspectives at MedAustron. U. Mock EBG MedAustron GmbH

Current Status and Future Medical Perspectives at MedAustron. U. Mock EBG MedAustron GmbH Current Status and Future Medical Perspectives at MedAustron U. Mock EBG MedAustron GmbH Cancer treatment facility Ion beam therapy with protons and carbon ions Research facility Medical physics Radiobiology

More information

Racial differences in six major subtypes of melanoma: descriptive epidemiology

Racial differences in six major subtypes of melanoma: descriptive epidemiology Wang et al. BMC Cancer (2016) 16:691 DOI 10.1186/s12885-016-2747-6 RESEARCH ARTICLE Racial differences in six major subtypes of melanoma: descriptive epidemiology Yu Wang 1, Yinjun Zhao 2 and Shuangge

More information

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David

More information

Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004

Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004 MCSS Epidemiology Report 04:2 Suggested citation Perkins C, Bushhouse S.. Minnesota Cancer Surveillance System. Minneapolis, MN, http://www.health.state.mn.us/divs/hpcd/ cdee/mcss),. 1 Background Cancer

More information

The Barbados National Registry for Chronic Non-Communicable Disease: a collaboration with the Barbados Ministry of Health

The Barbados National Registry for Chronic Non-Communicable Disease: a collaboration with the Barbados Ministry of Health The Barbados National Registry for Chronic Non-Communicable Disease: a collaboration with the Barbados Ministry of Health Angela MC Rose, Director, BNR Christina Howitt, Registrar, BNR Cancer PAHO-IARC

More information

FORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute

FORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute FORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute Charlotte, NC National Accreditation Program for Breast

More information

Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma

Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Karia, et al Methods Details of data collectionfeatures of primary tumors including anatomic

More information

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received

More information

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

GUIDELINES FOR ICD O 3 HISTOLOGY CODE AND BEHAVIOR UPDATE IMPLEMENTATION Effective January 1, 2018

GUIDELINES FOR ICD O 3 HISTOLOGY CODE AND BEHAVIOR UPDATE IMPLEMENTATION Effective January 1, 2018 North American Association of Central Registries, Inc GUIDELINES FOR ICD O 3 HISTOLOGY CODE AND BEHAVIOR UPDATE IMPLEMENTATION Effective January 1, 2018 Prepared by: NAACCR ICD O 3 Update Implementation

More information

Model Selection Methods for Cancer Staging and Other Disease Stratification Problems. Yunzhi Lin

Model Selection Methods for Cancer Staging and Other Disease Stratification Problems. Yunzhi Lin Model Selection Methods for Cancer Staging and Other Disease Stratification Problems by Yunzhi Lin A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY

More information

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA

More information

Doctor, How Am I Doing? Conditional Survival Analyses

Doctor, How Am I Doing? Conditional Survival Analyses Doctor, How Am I Doing? Conditional Survival Analyses Background Survival rates usually reported from time of diagnosis only Doesn't reflect changing hazard rates over time: early: higher hazard rate late:

More information

Pancreatic Cancer in Florida ( ) Prepared by: Lydia Voti, M.S. Florida Cancer Data System PO Box (D4-11) Miami, FL

Pancreatic Cancer in Florida ( ) Prepared by: Lydia Voti, M.S. Florida Cancer Data System PO Box (D4-11) Miami, FL Pancreatic Cancer in Florida (-) 9/1/ Prepared by: Lydia Voti, M.S. Florida Cancer Data System PO Box 19 (D-11) Miami, FL 3313 3-3- About the pancreas and its functions Introduction The pancreas is a -inch

More information

Bladder cancer: National Collaborating Centre for Cancer. diagnosis and management. Clinical Guideline. 28 July 2014.

Bladder cancer: National Collaborating Centre for Cancer. diagnosis and management. Clinical Guideline. 28 July 2014. National Collaborating Centre for Cancer Bladder cancer Bladder cancer: diagnosis and management Clinical Guideline Needs Assessment - full report July Draft for Consultation Commissioned by the National

More information

ISO INTERNATIONAL STANDARD. Dentistry Periodontal curettes, dental scalers and excavators Part 2: Periodontal curettes of Gr-type

ISO INTERNATIONAL STANDARD. Dentistry Periodontal curettes, dental scalers and excavators Part 2: Periodontal curettes of Gr-type INTERNATIONAL STANDARD ISO 13397-2 Second edition 2005-06-15 Dentistry Periodontal curettes, dental scalers and excavators Part 2: Periodontal curettes of Gr-type Art dentaire Curettes parodontales, instruments

More information

Annual Report 2016 of the Certified Prostate Cancer Centres

Annual Report 2016 of the Certified Prostate Cancer Centres Annual Report 2016 of the Certified Prostate Cancer Centres Audit year 2015 / Indicator year 2014 Content Introduction..... Status of the certification system: Prostate Cancer Centres 2015... General information.....

More information

Q&A on HIV/AIDS estimates

Q&A on HIV/AIDS estimates Q&A on HIV/AIDS estimates 07 Last updated: November 2007 Understanding the latest estimates of the 2007 AIDS Epidemic Update Part one: The data 1. What data do UNAIDS and WHO base their HIV prevalence

More information

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1 Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1

More information

AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna

AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases

More information

Enrollment Form: Pancreas

Enrollment Form: Pancreas Tissue Source Site (TSS) Name: TSS Identifier: _ TSS Unique Patient #: Completed By: Completion Date (MM/DD/YYYY): Form Notes: An Enrollment Form should be completed for each TCGA qualified case upon qualification

More information

Incidence of Cancers Associated with Modifiable Risk Factors and Late Stage Diagnoses for Cancers Amenable to Screening Idaho

Incidence of Cancers Associated with Modifiable Risk Factors and Late Stage Diagnoses for Cancers Amenable to Screening Idaho Incidence of Cancers Associated with Modifiable Risk Factors and Late Stage Diagnoses for Cancers Amenable to Screening Idaho 2008-2011 August 2013 A Publication of the Cancer Data Registry of Idaho PO

More information

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji

More information

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current

More information

The TNM classification is a worldwide benchmark for reporting the

The TNM classification is a worldwide benchmark for reporting the 1 COMMENTARY The Process for Continuous Improvement of the TNM Classification Mary K. Gospodarowicz, M.D. 1 Daniel Miller, M.D., M.P.H. 2 Patti A. Groome, M.Sc., Ph.D. 3 Frederick L. Greene, M.D. 4 Pamela

More information

ISO 7405 INTERNATIONAL STANDARD. Dentistry Evaluation of biocompatibility of medical devices used in dentistry

ISO 7405 INTERNATIONAL STANDARD. Dentistry Evaluation of biocompatibility of medical devices used in dentistry INTERNATIONAL STANDARD ISO 7405 Second edition 2008-12-15 Dentistry Evaluation of biocompatibility of medical devices used in dentistry Art dentaire Évaluation de la biocompatibilité des dispositifs médicaux

More information

ISO 660 INTERNATIONAL STANDARD. Animal and vegetable fats and oils Determination of acid value and acidity

ISO 660 INTERNATIONAL STANDARD. Animal and vegetable fats and oils Determination of acid value and acidity INTERNATIONAL STANDARD ISO 660 Third edition 2009-06-15 Animal and vegetable fats and oils Determination of acid value and acidity Corps gras d'origines animale et végétale Détermination de l'indice d'acide

More information

Local and Systemic Recurrence is the Achilles Heel of Cancer Surgery

Local and Systemic Recurrence is the Achilles Heel of Cancer Surgery Ann Surg Oncol (2011) 18:603 607 DOI 10.1245/s10434-010-1442-0 EDITORIAL Local and Systemic Recurrence is the Achilles Heel of Cancer Louis A. Aliperti 1, Jarrod D. Predina 1, Anil Vachani 2, and Sunil

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

Population based studies in Pancreatic Diseases. Satish Munigala

Population based studies in Pancreatic Diseases. Satish Munigala Population based studies in Pancreatic Diseases Satish Munigala 1 Definition Population-based studies aim to answer research questions for defined populations 1 Generalizable to the whole population addressed

More information

Format Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te

Format Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te Florida Cancer Data System International Classification of Diseases for Oncology ICD-O-3 1 Basic Concepts Primary Site/Topography Histology/Morphology Behavior Grade/Immunophenotype 2 ICD-O 3 Structure/Format

More information

Numerical Integration of Bivariate Gaussian Distribution

Numerical Integration of Bivariate Gaussian Distribution Numerical Integration of Bivariate Gaussian Distribution S. H. Derakhshan and C. V. Deutsch The bivariate normal distribution arises in many geostatistical applications as most geostatistical techniques

More information

Precision diagnostics for personalized melanoma care

Precision diagnostics for personalized melanoma care Precision diagnostics for personalized melanoma care The MelaGenix Gene Expression Test Helping your doctor find the right melanoma treatment for you Learning that the tiny mole on your body is actually

More information

SAMPLE. Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012

SAMPLE. Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012 Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012 The Renal Cell Carcinoma (RCC) Disease Therapeutics Market GlobalData s analysis suggests

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

Breast Cancer Staging

Breast Cancer Staging Breast Cancer Staging Symposium on Best Practice in Recording Cancer Stage Royal College of Pathologists 10 June 2011 Dr Gill Lawrence, Director Tel: 0121 415 8129 Fax: 0121 414 7712 Email: gill.lawrence@wmciu.nhs.uk

More information

Summary BREAST CANCER - Early Stage Breast Cancer... 3

Summary BREAST CANCER - Early Stage Breast Cancer... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential

More information

EFFECT OF RADIATION THERAPY ON SURVIVAL IN PATIENTS WITH RESECTED MERKEL CELL CARCINOMA: A POPULATION-BASED ANALYSIS JULIAN A. KIM, M.D.

EFFECT OF RADIATION THERAPY ON SURVIVAL IN PATIENTS WITH RESECTED MERKEL CELL CARCINOMA: A POPULATION-BASED ANALYSIS JULIAN A. KIM, M.D. EFFECT OF RADIATION THERAPY ON SURVIVAL IN PATIENTS WITH RESECTED MERKEL CELL CARCINOMA: A POPULATION-BASED ANALYSIS by JULIAN A. KIM, M.D. Submitted in partial fulfillment of the requirements For the

More information

Hong-Gyun Wu, M.D., Charn Il Park, M.D., S ung Whan Ha, M.D., and Il Han Kim, M.D.

Hong-Gyun Wu, M.D., Charn Il Park, M.D., S ung Whan Ha, M.D., and Il Han Kim, M.D. J. Korean Soc Ther Radiol Oncol 1999;17(1):108 112 1) S ign ifica nce of S uprac lav ic ula r Lymph Node Invo lve me nt o n Dete rm inat io n of Clin ica l Stag ing fo r Tho rac ic Es o phagea l Ca rc

More information

ON-LINE REGISTRATION FCDS MONOGRAPH: 2004 ADMISSIONS (TOTAL), ANALYTIC CASES ONLY FLORIDA ANNUAL CANCER REPORT: 2001 INCIDENCE

ON-LINE REGISTRATION FCDS MONOGRAPH: 2004 ADMISSIONS (TOTAL), ANALYTIC CASES ONLY FLORIDA ANNUAL CANCER REPORT: 2001 INCIDENCE ON-LINE REGISTRATION FOR THE FCDS ANNUAL CONFERENCE, JULY 27-28, 2006, AND BROCHURE FCDS 2006 IMPLEMENTATION GUIDE FOR NAACCR VERSION 11 (REVISED 5/22/2006; ADDS NEW AND UPDATED EDITS FOR CASES RECEIVED

More information

Causes of death in men with prostate cancer: an analysis of men from the Thames Cancer Registry

Causes of death in men with prostate cancer: an analysis of men from the Thames Cancer Registry Causes of death in men with prostate cancer: an analysis of 5 men from the Thames Cancer Registry Simon Chowdhury, David Robinson, Declan Cahill*, Alejo Rodriguez-Vida, Lars Holmberg and Henrik Møller

More information

Cancer Services Performance Indicators. Data Collection Method 2014

Cancer Services Performance Indicators. Data Collection Method 2014 Cancer Services Performance Indicators Data Collection Method 2014 Contents 1. Introduction... 4 2. Data collection period... 5 3. Patient sample... 5 3.1 Identification of the patient sample... 5 3.2

More information

Who What When Where Why. Case Finding 5 W s. NAACCR Webinar Series. Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC

Who What When Where Why. Case Finding 5 W s. NAACCR Webinar Series. Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC Who What When Where Why Case Finding 5 W s NAACCR 2010-2011 Webinar Series Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC Agenda Case Finding Purpose Reportable lists Benign intracranial

More information

Oral Cavity and Oropharynx Cancer Trends

Oral Cavity and Oropharynx Cancer Trends Oral Cavity and Oropharynx Cancer Trends Darien Weatherspoon, DDS, MPH Diplomate, American Board of Dental Public Health Program Officer, National Institute of Dental and Craniofacial Research National

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way

ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING Central Valley Public Health: Women's Way ICD-9-CM (Top 35) ICD-10-CM ICD-10-CM Description COMMENTS V10.3: Personal history of malignant neoplasm of Z85.3

More information

The lung cancer cure rate is dismal and has. The Effect of Tumor Size on Curability of Stage I Non-small Cell Lung Cancers*

The lung cancer cure rate is dismal and has. The Effect of Tumor Size on Curability of Stage I Non-small Cell Lung Cancers* The Effect of Tumor Size on Curability of Stage I Non-small Cell Lung Cancers* Juan P. Wisnivesky, MD, MPH; David Yankelevitz, MD; and Claudia I. Henschke, PhD, MD, FCCP Objective: The objective of this

More information

FINALIZED SEER SINQ S NOVEMBER 2011

FINALIZED SEER SINQ S NOVEMBER 2011 : 20110133 Multiple primaries/heme & Lymphoid Neoplasms: A patient was diagnosed 7/31/08 with DLBCL (9680/3) (biopsy left supraclav. node), stage IIIB. Treated with chemo. 10/14/10 biopsy right supraclav.

More information

Clinical Case Conference

Clinical Case Conference Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3

More information

Common Misunderstandings of Survival Time Analysis

Common Misunderstandings of Survival Time Analysis Common isunderstandings of Survival Time Analysis ilensu Shanyinde Centre for Statistics in edicine University of Oxford 2 nd April 2012 Outline Introduction Essential features of the Kaplan-eier survival

More information

Structured Follow-Up after Colorectal Cancer Resection: Overrated. R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007

Structured Follow-Up after Colorectal Cancer Resection: Overrated. R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007 Structured Follow-Up after Colorectal Cancer Resection: Overrated R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007 Guidelines for Colonoscopy Production: Surveillance US Multi-Society

More information

National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England:

National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England: National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England: 2001-2010 Trends in incidence and outcome for haematological cancers in England: 2001-2010 About

More information

Radiology- Pathology Conference 4/29/2012. Lymph Nodes. John McGrath

Radiology- Pathology Conference 4/29/2012. Lymph Nodes. John McGrath Radiology- Pathology Conference 4/29/2012 Lymph Nodes John McGrath 1 Presentation material is for education purposes only. All rights reserved. 2012 URMC Radiology Page 1 of 24 Case 1: 51 year-old male

More information